Analysis of drug-related problems in ischemic stroke in-patients in one Indonesian district hospital
Open Access
- 1 April 2024
- journal article
- research article
- Published by International Pharmaceutical Federation (FIP) in Pharmacy Education
- Vol. 24 (2) , 134-139
Abstract
Background: Ischemic stroke is one of the leading causes of death in Indonesia. Appropriate management, including the identification of drug-related problems (DRPs), is needed to prevent disability and death. Objective: This study aimed to analyse DRPs as defined by the Pharmaceutical Care Network Europe (PCNE). Method: This was a cross-sectional research using the medical records of in-patients with ischemic stroke aged >18 years. Result: Out of the 115 patients examined, 51.3% were male, and the mean age was 57.85 + 10.539 years. Exactly 204 cases of DRPs and 175 causes appeared in 101 patients. A total of 58 patients experienced one-to-two problems, and 43 patients experienced more than two problems. The problems domain consists of therapeutic effectiveness (P1, 133(65.2%)), adverse effects (P2, 67(32, 84%)), and medical expenses (P3, 4(1, 96%)). The DRPs mostly involved antihypertension and antiplatelet. The most common cause was a new indication for treatment (C1.9, 51(29.14%)) and drug interactions (C8.1, 48(27.43%)). Multivariate analysis of patient characteristics showed that patients taking more than eight medications were more likely to experience more than two DRPs than those on one-to-four medications (OR 5.593; 95%, CI 1.015-30.812). Conclusion: Most patients experienced one-to-two DRPs with the highest being a potentially suboptimal treatment. Clinical pharmacists are expected to monitor therapy, especially in polypharmacy patients.Keywords
This publication has 16 references indexed in Scilit:
- Drug-related problems among community-dwelling elderly with ischemic stroke in ChinaAdvances in Clinical and Experimental Medicine, 2023
- Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019The Lancet Neurology, 2021
- Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic AttackStroke, 2021
- Prevalence of adverse drug reactions in the primary care setting: A systematic review and meta-analysisPLOS ONE, 2021
- Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney FunctionJAMA Internal Medicine, 2018
- A study of potential adverse drug-drug interactions among prescribed drugs in medicine outpatient department of a tertiary care teaching hospitalJournal of Basic and Clinical Pharmacy, 2014
- Antiplatelet therapy - a pharmacologist's perspectiveCor et Vasa, 2013
- Effects of Statins on Skeletal Muscle: A Perspective for Physical TherapistsPhysical Therapy, 2010
- Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrelJournal of Thrombosis and Haemostasis, 2010
- Calcium-channel blockers decrease clopidogrel-mediated platelet inhibitionHeart, 2009